Biotech Companies Experience Growth

JULY 01, 2005

The biotechnology industry is coming into its own, according to Beyond Borders, Ernst & Young's 19th Annual Global Biotechnology report. With governmental support and private capital, biotech companies worldwide are translating cutting-edge science into life-improving therapies. The industry's success in 2004 included:

  • The approval of 20 new biotech medicines in the United States.
  • Biotech companies now market approximately 230 drugs, including 13 therapeutic antibodies. In addition, 55 new drug applications await approval in the United States alone.

"Biotech innovation is a key value driver for the pharmaceutical industry, as more than half of its late-stage pipeline now consists of therapeutics generated using biotechnology advances," said Mike Hildreth, Americas director, biotechnology, Ernst &Young.



SHARE THIS SHARE THIS
0
 

In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine

Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.


 

 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.